PE20020305A1 - 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA - Google Patents

2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA

Info

Publication number
PE20020305A1
PE20020305A1 PE2001000776A PE2001000776A PE20020305A1 PE 20020305 A1 PE20020305 A1 PE 20020305A1 PE 2001000776 A PE2001000776 A PE 2001000776A PE 2001000776 A PE2001000776 A PE 2001000776A PE 20020305 A1 PE20020305 A1 PE 20020305A1
Authority
PE
Peru
Prior art keywords
pyrimidin
alkyl
dialcoxyphenyl
onas
pyridyl
Prior art date
Application number
PE2001000776A
Other languages
English (en)
Inventor
James Marino Hamby
James Bernard Kramer
Sylvester Klutchko
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020305A1 publication Critical patent/PE20020305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS DE FORMULA I DONDE R1, R2, R5 Y R6 SON H, HALO, ALQUILO C1-C6, ALCOXI C1-C6, TIOALQUILO, HIDROXI, ALCANOILO C1-C6, ALCOXI C1-C6, TIO, TIOALQUILO, ENTRE OTROS; R3 Y R4 SON ALQUILO C1-C6, HALOALQUILO C1-C6; R7 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, CILOALQUILO C3-C6. SON COMPUESTOS PREFERIDOS 6-(3,5-DIMETOXI-FENIL)-2-(2-METIL-PIRIDIN-4-ILAMINO)-8-ETIL-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA, 6-(3,5-DIMETOXI-FENIL)-2-(2,6-DIMETIL-PIRIDIN-4-ILAMINO)-8-ETIL-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA, 6-(3,5-DIMETOXI-FENIL)-2-(2-CLORO-PIRIDIN-4-ILAMINO)-8-ETIL-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS SON INHIBIDORES DE LA TIROSINA QUINASA UTILES PARA TRATAR ENFERMEDADES DERIVADAS DE LA PROLIFERACION CELULAR COMO CANCER, ATEROSCLEROSIS, RESTENOSIS, ARTRITIS REUMATOIDE
PE2001000776A 2000-08-04 2001-08-03 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA PE20020305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22308300P 2000-08-04 2000-08-04

Publications (1)

Publication Number Publication Date
PE20020305A1 true PE20020305A1 (es) 2002-05-09

Family

ID=22834955

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000776A PE20020305A1 (es) 2000-08-04 2001-08-03 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA

Country Status (21)

Country Link
US (1) US7022711B2 (es)
EP (1) EP1307450B1 (es)
JP (1) JP2004519422A (es)
AP (1) AP1333A (es)
AR (1) AR030310A1 (es)
AT (1) ATE408613T1 (es)
AU (1) AU2001277032A1 (es)
BR (1) BR0112857A (es)
CA (1) CA2417942C (es)
DE (1) DE60135854D1 (es)
DO (1) DOP2001000227A (es)
ES (1) ES2311532T3 (es)
GT (1) GT200100158A (es)
HN (1) HN2001000171A (es)
MX (1) MXPA02011263A (es)
PA (1) PA8524101A1 (es)
PE (1) PE20020305A1 (es)
SV (1) SV2002000572A (es)
TN (1) TNSN01118A1 (es)
UY (1) UY26867A1 (es)
WO (1) WO2002012238A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424057A1 (en) * 2000-08-04 2003-04-03 Warner-Lambert Company Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido [2,3-d]pyrimidin-7-ones
JP2004505974A (ja) * 2000-08-04 2004-02-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
ATE314370T1 (de) * 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2004013633A2 (en) * 2002-07-29 2004-02-12 Axxima Pharmaceuticals Ag Method for isolating atp binding proteins by means of immobolized protein inhibitors
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
RU2006107553A (ru) 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004289304A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
EP2260849A1 (en) 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20090088854A (ko) * 2006-09-13 2009-08-20 다케다 야쿠힌 고교 가부시키가이샤 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
EP2094698A1 (en) * 2006-11-09 2009-09-02 F. Hoffmann-Roche AG Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
BR112012033770A2 (pt) 2010-06-30 2016-11-22 Fujifilm Corp novo derivado de nicotinamida ou sal do mesmo
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
DK2872491T3 (da) * 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
CN111793068A (zh) * 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018005865A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
RU2745035C1 (ru) * 2017-02-27 2021-03-18 Бетта Фармасьютикалз Ко., Лтд. Ингибитор fgfr и его применение
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
KR102531596B1 (ko) * 2018-09-14 2023-05-11 아비스코 테라퓨틱스 컴퍼니 리미티드 Fgfr억제제, 그 제조 방법 및 용도
EP3902801A4 (en) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022150415A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
CA2424057A1 (en) * 2000-08-04 2003-04-03 Warner-Lambert Company Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido [2,3-d]pyrimidin-7-ones
JP2004505974A (ja) * 2000-08-04 2004-02-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法

Also Published As

Publication number Publication date
CA2417942C (en) 2010-06-29
ES2311532T3 (es) 2009-02-16
PA8524101A1 (es) 2002-10-24
JP2004519422A (ja) 2004-07-02
WO2002012238A2 (en) 2002-02-14
EP1307450B1 (en) 2008-09-17
TNSN01118A1 (en) 2005-11-10
UY26867A1 (es) 2001-10-25
SV2002000572A (es) 2002-07-18
ATE408613T1 (de) 2008-10-15
BR0112857A (pt) 2005-02-09
US7022711B2 (en) 2006-04-04
MXPA02011263A (es) 2003-03-10
US20030220345A1 (en) 2003-11-27
EP1307450A2 (en) 2003-05-07
HN2001000171A (es) 2001-09-21
GT200100158A (es) 2002-07-18
AR030310A1 (es) 2003-08-20
WO2002012238A3 (en) 2002-05-10
AU2001277032A1 (en) 2002-02-18
AP1333A (en) 2004-11-28
CA2417942A1 (en) 2002-02-14
DOP2001000227A (es) 2002-12-15
AP2001002230A0 (en) 2001-09-30
DE60135854D1 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
MX2007004781A (es) Derivados de 3-arilamino piridina.
BG102003A (en) PYRIDO/2,3-d/PYRIMIDINES FOR THE INHIBITION OF CELLULAR PROLIFERATION CAUSED BY PROTEINTHYROSIKINASE
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
BRPI0411365A (pt) derivados de aminopiridina
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
NO20073393L (no) [1,2,4]tnazolo [4,3-A] pyridin derivater for behandlingen av hyperproliferative sykdommer
AP1860A (en) Aryl fused azapolycyclic compounds.
YU84603A (sh) Novi inhibitori tirozin kinaze
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
TW200420562A (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
MXPA03004347A (es) Nuevos derivados de imidazol, metodo de produccion y uso de los mismos.
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
EP0994113A3 (en) 7-Aminopyrido(2,3-d)-pyrimidine derivatives for treatment of bronchial asthma
CA2484340A1 (en) 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
PT1072601E (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
PE20020260A1 (es) Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido [2,3-d]pirimidin-7-onas
PT1282625E (pt) Benzoxazinas para utilizacao no tratamento da doenca de parkinson
MXPA01008308A (es) Proceso para la preparacion de compuestos de 6-(perfluoroalquil) uracilo.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed